Safety and efficacy of non-vitamin K antagonist oral anticoagulants for prevention of thromboembolism in adults with systemic right ventricle: Results from the NOTE international registry.

Scognamiglio, Giancarlo; Fusco, Flavia; Hankel, Tara C; Bouma, Berto J; Greutmann, Matthias; Khairy, Paul; Ladouceur, Magalie; Dimopoulos, Konstantinos; Niwa, Koichiro; Broberg, Craig S; Miranda, Berta; Budts, Werner; Bouchardy, Judith; Schwerzmann, Markus; Lipczyńska, Magdalena; Tobler, Daniel; Tsai, Shane F; Egbe, Alexander C; Aboulhosn, Jamil; Fernandes, Susan M; ... (2021). Safety and efficacy of non-vitamin K antagonist oral anticoagulants for prevention of thromboembolism in adults with systemic right ventricle: Results from the NOTE international registry. International journal of cardiology, 322, pp. 129-134. Elsevier 10.1016/j.ijcard.2020.08.034

Text 1-s2.0-S0167527320335610-main_2_.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (627kB) | Request a copy

BACKGROUND

Patients with systemic right ventricle (sRV), including transposition of great arteries (TGA) after atrial switch procedure and congenitally corrected transposition of great arteries (ccTGA), may require anticoagulation for thromboembolism (TE) prevention. In the absence of data on non-vitamin K antagonist oral anticoagulants (NOACs), vitamin K antagonists (VKAs) remain the agent of choice. We investigated the safety, efficacy and feasibility of NOACs treatment in adults with sRV in a worldwide study.

METHODS

This is an international multicentre prospective study, using data from the NOTE registry on adults with sRV taking NOACs between 2014 and 2019. The primary endpoints were TE and major bleeding (MB). The secondary endpoint was minor bleeding.

RESULTS

A total of 76 patients (42.5 ± 10.0 years, 76% male) with sRV (74% TGA, 26% ccTGA) on NOACs were included in the study. During a median follow-up of 2.5 years (IQR1.5-3.9), TE events occurred in 3 patients (4%), while no MB episodes were reported. Minor bleeding occurred in 9 patients (12%). NOAC treatment cessation rate was 1.4% (95%CI:0.3-4%) during the first year of follow-up. All the patients with TE events had a CHA2DS2-VASc score ≥ 2 and impaired sRV systolic function at baseline. The total incidence of major events during follow-up was significantly lower compared to historical use of VKAs or aspirin before study inclusion (1.4% (95%CI:0.29-4%) vs 6,9% (95%CI:2.5-15.2%); p = .01).

CONCLUSIONS

In this prospective study, NOACs appear to be well-tolerated, with excellent efficacy and safety at mid-term in patients with sRV.

Interest & Impact

Downloads

2 since deposited on 10 Feb 2022
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item